Ionis Pharmaceuticals Reports Pelacarsen Phase 3 Trial Missed Primary Endpoint

What Happened

• On September 4, 2026, Ionis Pharmaceuticals announced (via press release) that partner Novartis reported the pelacarsen Phase 3 Lp(a)HORIZON cardiovascular outcomes trial did not meet its primary endpoint of reducing the risk of cardiovascular events versus placebo. The primary endpoint was a composite of cardiovascular death, non‑fatal myocardial infarction, non‑fatal stroke, and urgent coronary revascularization requiring hospitalization.
• The filing notes that pelacarsen did produce substantially lower lipoprotein(a) [Lp(a)] levels and demonstrated an acceptable safety profile. Ionis discovered and led early development of pelacarsen; Novartis exercised its option to license development and commercialization rights in February 2019. Full Lp(a)HORIZON data will be presented at an upcoming medical congress.

Key Details

• Date of announcement and Form 8‑K filing: September 4, 2026.
• Trial: Phase 3 Lp(a)HORIZON (cardiovascular outcomes); primary endpoint = composite of cardiovascular death, non‑fatal MI, non‑fatal stroke, urgent coronary revascularization requiring hospitalization.
• Biomarker and safety: Pelacarsen achieved substantially lower Lp(a) levels versus placebo and had an acceptable safety profile (per Novartis report).
• Partnership history: Ionis discovered and completed early development; Novartis licensed global rights in Feb 2019.

Why It Matters

• For investors, the failure to meet the primary cardiovascular endpoint is a material clinical setback for pelacarsen’s goal of reducing major cardiovascular events, which could affect its regulatory and commercial prospects under Novartis’ development plan.
• Offsetting factors in the filing: pelacarsen lowered Lp(a) (the intended biomarker) and showed an acceptable safety profile, and full results will be disclosed at a medical congress — those details will be important for assessing whether any subgroups, secondary endpoints, or additional analyses change the program’s outlook.
• Ionis remains a discovery/early‑development partner for pelacarsen; further financial or milestone impacts depend on Novartis’ decisions and the forthcoming full dataset. Investors should review Ionis’ risk disclosures in its most recent Form 10‑K and Form 10‑Q for additional context.